Compare · CVKD vs NVO
CVKD vs NVO
Side-by-side comparison of Cadrenal Therapeutics Inc. (CVKD) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CVKD and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $211.73B, about 22478.0x CVKD ($9.4M).
- Over the past year, CVKD is down 70.9% and NVO is down 33.0% - NVO leads by 37.9 points.
- CVKD has been more active in the news (11 items in the past 4 weeks vs 3 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 1 for CVKD).
- Company
- Cadrenal Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $3.19-6.73%
- $47.40+3.29%
- Market cap
- $9.4M
- $211.73B
- 1M return
- -37.33%
- +6.83%
- 1Y return
- -70.87%
- -32.98%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2023
- News (4w)
- 11
- 3
- Recent ratings
- 1
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest CVKD
- Chairman, CEO and Interim CFO Pham Quang X sold $13,110 worth of shares (4,126 units at $3.18) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 128,589 units (SEC Form 4)
- Cadrenal Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Cadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease
- Chairman, CEO and Interim CFO Pham Quang X sold $70,352 worth of shares (18,124 units at $3.88) as part of a pre-agreed trading plan, decreasing direct ownership by 12% to 132,715 units (SEC Form 4)
- SEC Form 144 filed by Cadrenal Therapeutics Inc.
- Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026
- Chairman, CEO and Interim CFO Pham Quang X sold $93,294 worth of shares (22,385 units at $4.17) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 150,839 units (SEC Form 4)
- CEO and Chairman Pham Quang X sold $36,209 worth of shares (8,285 units at $4.37) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 173,224 units (SEC Form 4)
- Cadrenal Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Cadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 and Novel 12-LOX Platform at BIO International Convention 2026 Partnering Event
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S